Innocan Pharma's LPT-CBD Demonstrates Long-Term Pain Relief in Dogs with Osteoarthritis
Key Insights
Innocan Pharma (search)'s LPT-CBD showed sustained pain reduction and improved mobility in dogs with osteoarthritis (search) over a multi-year compassionate therapy.
The injectable treatment demonstrated efficacy in dogs that did not respond to NSAIDs (search) and oral CBD, enhancing their quality of life.
LPT-CBD offers superior bioavailability by avoiding first-pass liver metabolism, positioning it as a potential monthly treatment for chronic pain.
Innocan Pharma (search) Corporation announced positive results from a multi-year compassionate therapy using repeated liposomal-CBD (LPT-CBD) injections for managing pain in dogs suffering from naturally-occurring osteoarthritis (search). The study demonstrated consistent pain reduction and improved mobility, with the effects lasting several weeks following each injection.
Sustained Pain Relief with LPT-CBD
The ongoing cases involved dogs with osteoarthritis (search) that had previously shown no improvement with non-steroidal anti-inflammatory drugs (NSAIDs (search)) and oral CBD treatments. After being administered LPT-CBD, these dogs exhibited noticeable pain relief, significantly improved mobility, and an overall increase in well-being. The dogs remained on LPT-CBD treatment for 2 and 2.5 years, respectively, with owners reporting a marked improvement in their pets' quality of life when the treatment was added to conventional therapies. Prior pilot studies conducted by Innocan have yielded similarly encouraging results.
Mechanism of Action and Potential Benefits
LPT-CBD, administered as a monthly injectable treatment, potentially offers superior bioavailability by bypassing first-pass liver metabolism. This method could allow for more efficient delivery of CBD, enhancing its therapeutic effects.
Expert Commentary
"We are thrilled with these findings, which highlight the long-lasting effects of repeated administration of LPT-CBD to treat chronic pain," commented Professor Chezy Barenholz, CSO of Innocan Pharma (search). "These results support the potential of LPT-CBD as a monthly treatment for chronic pain conditions, providing sustained relief. They position LPT-CBD as a breakthrough solution for managing chronic pain in animals and, by extension, human patients."
Dr. Eyal Kalo, R&D Director at Innocan, added, "This compassionate therapy has demonstrated significant efficacy in companion dogs and reinforces our commitment to advance FDA's Center for Veterinary Medicine (CVM) approval of LPT-CBD for the treatment of chronic pain in dogs."